quinazolines has been researched along with nvp-aew541 in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kwan, W; Liu, S; Lubieniecka, JM; Nielsen, TO; Terry, J | 1 |
Abraham, J; Efstratiadis, A; Giles, FG; Keller, C; Kilcoyne, A; LeGallo, RD; Malempati, S; McCleish, AT; Nelon, LD; Nishijo, K; Nowak, BM; Prajapati, SI; Rubin, BP; Schaffer, BS; Taniguchi, E | 1 |
Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM | 1 |
Baxter, RC; Gill, AJ; Hugh, TJ; Julovi, SM; Pavlakis, N; Peters, L; Samra, JS; Smith, RC; Wong, MH; Xue, A | 1 |
Bubendorf, L; Erne, P; Frachet, A; Frismantiene, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ; Ruiz, C; Vlajnic, T | 1 |
Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU | 1 |
6 other study(ies) available for quinazolines and nvp-aew541
Article | Year |
---|---|
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Inhibitory Concentration 50; Lactams, Macrocyclic; Piperazines; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Sarcoma, Synovial; Trastuzumab | 2005 |
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Child; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Embryo, Mammalian; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Phosphorylation; Pyrimidines; Pyrroles; Quail; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; RNA Interference; Tumor Burden; Tumor Cells, Cultured; Young Adult | 2011 |
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
Topics: Afatinib; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Pancreatic Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1 | 2013 |
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Survival; Collagen; Drug Combinations; ErbB Receptors; Gefitinib; Gene Silencing; Golgi Apparatus; Humans; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphorylation; Prostate; Prostatic Neoplasms; Proteoglycans; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1 | 2015 |
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2017 |